Risk factors for severe respiratory syncytial virus lower respiratory tract infection

Open Microbiology Journal

Volumn 5, Issue SPEC. ISSUE 2, 2011, Pages 144-154

  Sommer, Constanze ^a   Resch, Bernhard ^a   Simões, Eric A F ^b,c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF COLORADO   (United States)

^c PADJADJARAN UNIVERSITY   (Indonesia)

Author keywords

Cellular immunity; Iga antibodies; Immune complex reaction; Rsv disease; Syncytial virus

Indexed keywords

IMMUNOGLOBULIN; PALIVIZUMAB; PLACEBO;

ALTITUDE; ARTICLE; ASTHMA; BREAST FEEDING; CHILD HEALTH CARE; CIGARETTE SMOKING; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN SYNDROME; DRUG EFFICACY; EDUCATIONAL STATUS; FAMILY HISTORY; HIGH RISK INFANT; HIGH RISK PATIENT; HOME OXYGEN THERAPY; HUMAN; INFECTION PREVENTION; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; LUNG DYSPLASIA; MALNUTRITION; MULTIPLE PREGNANCY; NEUROMUSCULAR DISEASE; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEX DIFFERENCE; SMALL FOR DATE INFANT; SOCIAL STATUS; URBAN POPULATION; VIRUS TRANSMISSION;

RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84855755161     PISSN: None     EISSN: 18742858     Source Type: Journal    
DOI: 10.2174/1874285801105010144     Document Type: Article

References (65)

1. Nair H, Nokesc DJ, Gessnere BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545-55.
2. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140: 543-6.
3. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009; 15: 34-41.
4. Schmidt AC, Johnson TR, Openshaw PJM, et al. Respiratory syncytial virus and other pneumoviruses: a review of the international symposium-RSV 2003. Virus Res 2004; 106: 1-13.
5. th ed. 2004; 185A: 2315-41.
6. Wert SE. Normal and abnormal structural development of the lung. In: Polin RA, Fox WW, Abmann SH, Eds. Fetal and neonataly physiology. Philadelphia: Saunders 2004; pp 784-94.
7. Ballow M, Cates KL, Rowe JC, Goetz C, Desbonnet C. Development of the immune system in very low birth weight (less than 1500g) premature infants: concentration of plasma immunoglobulins and patterns of infections. Pediatr Res 1986; 20: 899-904.
8. De Sierra TM, Kumar ML, Wasser TE, Murphy BR, Subbarao EK. Respiratory syncytial virus-specific immunoglobulins in preterm infants. J Pediatr 1993; 122: 787-91.
9. Meert K, Heidemann S, Abella B, Sarnaik A. Does prematurity alter the course of respiratory syncytial virus infection? Crit Care Med 1990; 18: 1357-9.
10. Resch B, Gusenleitner W, Mueller W. The impact of respiratory syncytial virus infection: a prospective study in hospitalized infants younger than 2 years. Infection 2002; 30: 193-7.
11. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003; 143: 133-41.
12. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000; 154: 55-61.
13. American Academy of Pediatrics. Committee on Infectious Disease and Committee on Fetus and Newborn. Prevention of Respiratory Syncytical Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV. Pediatrics 1998; 102: 1211-6.
14. Carbonell-Estrany X, Quero J, Bustos G, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 2000; 19: 592-7.
15. Resch B, Pasnocht A, Gusenleitner W, Mueller W. Rehospitalizations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect 2005; 50: 397-403.
16. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004; 23: 806-14.
17. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al; IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008; 27: 788-93.
18. Gunville CF, Sontag MK, Stratton KA, et al. Scope and impact of early and late preterm infants admitted to the PICU with respiratory illness. J Pediatr 2010; 157: 209-14.
19. Thomas W, Speer CP. Bronchopulmonary dysplasia: epidemiology, pathogenesis and treatment. Monatsschrift Kinderheilkd 2005; 153: 211-9
20. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988; 82: 199-203.
21. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 93: 93-7.
22. The IMpact- RSV Study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduced hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-7.
23. Thomas M, Bedford-Russell A, Sharland M. Hospitalization for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch Dis Child 2000; 83: 122-7
24. Greenough A, Cox S, Alexander J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001; 85: 463-8.
25. Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH; Munich RSV Study Group. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003; 162: 230-6.
26. Simon A, Ammann RA, Wilkesmann A, et al; DSM RSV Paed Study Group. Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur J Pediatr 2007; 166: 1273-83.
27. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982; 307: 397-400.
28. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992; 121: 348-4.
29. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995; 126: 212-9.
30. American Academy of Pediatrcs. Committee on Infectious Disease and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infection: indication for the use of palivizumab and update on the use of RSV. IGIV. J Pediatr 1998; 102: 1211-6.
31. Feltes TF, Cabalka AK, Meissner HC, et al. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532-40.
32. American Academy of Pediatrics. Committee on Infectious Disease and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immunoglobulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112: 1442-6.
33. American Academy of Pediatrcs. Committee on Infectious Disease and committee on Fetus and Newborn. Modified recommandations for the use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124: 1694-701.
34. Cohen SA, Zanni R, Cohen A, Harrington M, VanVeldhuisen P, Boron ML; Palivizumab Outcomes Registry Group. Palivizumab use in subjects with congenital heart disease: results from the 2000-2004 Palivizumab Outcomes Registry. Pediatr Cardiol 2008; 29: 382-7.
35. Chang RK, Chen AY. Impact of palivizumab on RSV hospitalizations for children with hemodynamically significant congenital heart disease. Pediatr Cardiol 2010; 31: 90-5.
36. Kristensen K, Stensballe LG, Bjerre J, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009; 94: 785-9.
37. Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev 2009; 10: 148-53.
38. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virusspecific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001; 184: 350-4.
39. Thomas NJ, Hollenbeak CS, Ceneviva GD, Geskey JM, Young MJ. Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model. J Pediatr Hematol Oncol 2007; 29: 227-32.
40. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986; 315: 77-81.
41. Cole PD, Suh JS, Onel K, Stiles J, Armstrong D, Dunkel IJ. Benign outcome of RSV infection in children with cancer. Med Pediatr Oncol 2001; 37: 24-9.
42. King JC Jr, Burke AR, Clemens JD, et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and non-infected children. Pediatr Infect Dis J 1993; 12: 733-9.
43. Madhi SA, Schoub B, Simmank K, Blackburn N, Klugman KP. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr 2000; 137: 78-84.
44. Bloemers BLP, van Furth AM, Weijerman ME, et al. A novel risk factor for respiratory syncytical virus bronchiolitis- A prospective birth cohort study. Pediatrics 2007; 120: 1076-81.
45. Bloemers BLP, van Furth AM, Weijerman ME, et al. High incidence of recurrent wheeze in children with Down Syndrome with and without previous respiratory syncytial virus lower respiration tract infection. Pediar Infect Dis J 2010; 29: 39-42.
46. Law B, Mac Donald N, Langley J. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: what are we trying to prevent? Paediatr Child Health 1998; 3: 402-4.
47. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower tract disease. J Pediatr 2003; 143: 118-26.
48. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004; 23: 815-20.
49. Simoes EA, King SJ, Lehr MV, Groothuis JR. Preterm twins and triplets: a high- risk group for severe respiratory syncytial virus infection. Am J Dis Child 1993; 147: 303-6.
50. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk factors for respiratory syncytial virus infection for infants from low- income families in relation to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981; 98: 708-15.
51. Jansson L, Nilson P, Olsson M. Socioeconomic enviromental factors and hospitalization for acute bronchiolitis during infancy. Acta Paediatr 2002; 91: 335-8.
52. Anderson LJ, Parker RA, Strikas RA, Farrar JA, Gangarosa EJ, Keyserling HL. Day- care centre attendance and hospitalization for lower respiratory tract illness. Pediatrics 1988; 83: 300-8.
53. McConnochie KM, Roghmann KJ. Parental smoking, presence of older siblings, and family history of asthma increase risk of bronchiolitis. Am J Dis Child 1986; 140: 806-12.
54. Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD, Group Health Medical Associates. Risk factors for respiratory syncytial virus- associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991; 133: 1135-51.
55. Meissner HC. Commentary: The unresolved issue of risk factors for hospitalization of infants with respiratory syncytial virus infection born after 33-35 weeks gestation. Pediatr Infect Dis 2004; 23: 821-3.
56. Stensballe LG, Ravn H, Kristensen K, Meakins T, Aaby P, Simoes EA. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr 2009; 154: 296-8.
57. Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J 2003; 22: 21-32.
58. Choudhuri JA, Ogden LG, Ruttenber AJ, Thomas DS, Todd JK, Simoes EA. Effect of altitude on hospitalizations for respiratory syncytial virus infection. Pediatrics 2006; 117: 349-56.
59. Simões EA, Carbonell-Estrany X, Fullarton JR, et al. European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008; 9: 78.
60. Stensballe LG, Fullarton JR, Carbonell-Estrany X, Simões EA. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J 2010; 29: 374-6.
61. Carbonell-Estrany X, Simões EA, Fullarton JR, Ferdynus C, Gouyon JB; European RSV Risk Factor Study Group. Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation. J Perinat Med 2010; 38: 411-7.
62. Simões EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, Lanari M, European RSV Risk Factor Study Group. European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data. J Matern Fetal Neonatal Med 2011; 24: 152-7.
63. Simões EA, Carbonell-Estrany X, Fullarton JR, Rossi GA, Barberi I, Lanari M; European RSV Risk Factor Study Group. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Mak 2008; 28: 471-80.
64. Paes B, Steele S, Janes M, Pinelli J. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin 2009; 25: 1585-91.
65. Paes B, Cole M, Latchman A, Pinelli J. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada. Curr Med Res Opin 2009; 25: 2191-6.